KR20240107326A - Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물 - Google Patents

Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물 Download PDF

Info

Publication number
KR20240107326A
KR20240107326A KR1020247019391A KR20247019391A KR20240107326A KR 20240107326 A KR20240107326 A KR 20240107326A KR 1020247019391 A KR1020247019391 A KR 1020247019391A KR 20247019391 A KR20247019391 A KR 20247019391A KR 20240107326 A KR20240107326 A KR 20240107326A
Authority
KR
South Korea
Prior art keywords
week
subject
weeks
compound
mds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247019391A
Other languages
English (en)
Korean (ko)
Inventor
바네사 베이논
수만 조이 바티아
레니 당
멜리사 엘. 디바코
바르샤 브이. 아이어
찰스 쿵
메간 린치
오필리아 치핑 인
롤란다스 우르브스토나이티스
젠 샤오
Original Assignee
아지오스 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지오스 파마슈티컬스 아이엔씨. filed Critical 아지오스 파마슈티컬스 아이엔씨.
Publication of KR20240107326A publication Critical patent/KR20240107326A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020247019391A 2021-11-16 2022-11-15 Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물 Pending KR20240107326A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US63/280,069 2021-11-16
US202263357240P 2022-06-30 2022-06-30
US63/357,240 2022-06-30
PCT/US2022/049969 WO2023091414A1 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Publications (1)

Publication Number Publication Date
KR20240107326A true KR20240107326A (ko) 2024-07-09

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247019391A Pending KR20240107326A (ko) 2021-11-16 2022-11-15 Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물

Country Status (11)

Country Link
US (1) US20250108049A1 (https=)
EP (1) EP4433057A1 (https=)
JP (1) JP2024543345A (https=)
KR (1) KR20240107326A (https=)
AU (1) AU2022390088A1 (https=)
CA (1) CA3236880A1 (https=)
CL (1) CL2024001431A1 (https=)
IL (1) IL312679A (https=)
MX (1) MX2024005852A (https=)
TW (1) TW202329935A (https=)
WO (1) WO2023091414A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202509043A (zh) * 2023-05-15 2025-03-01 美商阿吉歐斯製藥公司 ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
TWI796353B (zh) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
WO2020237047A1 (en) 2019-05-22 2020-11-26 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Also Published As

Publication number Publication date
CA3236880A1 (en) 2023-05-25
JP2024543345A (ja) 2024-11-21
EP4433057A1 (en) 2024-09-25
TW202329935A (zh) 2023-08-01
CL2024001431A1 (es) 2024-10-25
US20250108049A1 (en) 2025-04-03
AU2022390088A1 (en) 2024-05-09
MX2024005852A (es) 2024-05-28
WO2023091414A1 (en) 2023-05-25
IL312679A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP7270688B2 (ja) 貧血治療のための組成物及び方法
KR102011641B1 (ko) 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
US20210100805A1 (en) Combination therapy for treating malignancies
JP2021098740A (ja) 悪性病変を処置する方法
JP2024507938A (ja) 骨髄線維症の治療としてのｂｅｔ阻害剤の使用
UA123400C2 (uk) Комбінована терапія для лікування злоякісних пухлин
RU2734930C2 (ru) Режимы дозирования мелфлуфена для раковых заболеваний
US20250108049A1 (en) Compounds for treating mds-associated anemias and other conditions
UA123401C2 (uk) Комбінована терапія для лікування злоякісних пухлин
WO2017042944A1 (ja) フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
TW201217361A (en) Method of treating abnormal cell growth
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
EP3137073A1 (en) Glyt1 inhibitors for use in the treatment of hematological disorders
CN103429239A (zh) 增加网织红细胞血红蛋白含量的方法
TW201936190A (zh) 用於治療癌症之芳基咪唑
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
TW202241415A (zh) 通路調節劑、含其的醫藥組成物、其用途和採用其的治療方法
JP7493503B2 (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
EA050684B1 (ru) Соединения для лечения анемий и других патологических состояний, ассоциированных с mds
KR20220124739A (ko) 암의 치료를 위한 병용 요법
TW202440116A (zh) 組合療法
JP7664429B2 (ja) Ｆｇｆｒ４選択的阻害剤の塩及びその製造方法と用途
CN118382439A (zh) 用于治疗mds相关贫血和其他病症的化合物
CA3254948A1 (en) Polytherapy for the treatment of cancer
WO2026076363A1 (en) Compounds for treating mds-associated anemias and other conditions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201